At a Glance
- Five-year strategic MoU between Moderna and the Government of Mexico
- Technology transfer to enable local mRNA vaccine manufacturing
- In-country production of Moderna’s COVID-19 and respiratory vaccines
- Collaboration to strengthen Mexico’s pandemic preparedness and R&D capacity
Written By: Pharmacally Medical News Desk
Moderna has entered into a five-year Memorandum of Understanding with the Government of Mexico to strengthen local vaccine manufacturing and improve long-term pandemic preparedness. The agreement brings together Moderna, the Mexican Government, Laboratorios de Biológicos y Reactivos de Mexico (BIRMEX), and Laboratorios Liomont (Liomont).
Under the agreement, Moderna will supply its respiratory vaccine portfolio to Mexico while transferring mRNA manufacturing technology to Liomont. The technology transfer will enable local production of mRNA-1273, Moderna’s COVID-19 vaccine, creating a stable in-country supply of respiratory vaccines and reducing reliance on external manufacturing.
The collaboration aligns with Mexico’s “Plan Mexico” initiative, which aims to boost domestic production capacity and attract strategic investment. Beyond manufacturing, Moderna and the Mexican Government will work together on locally driven clinical research and development programs that reflect national health priorities. The partnership also includes efforts to strengthen Mexico’s pandemic preparedness framework.
Commenting on the agreement, Stéphane Bancel, Chief Executive Officer of Moderna, said the collaboration supports Mexico’s goal of reinforcing national health security while expanding access to Moderna’s respiratory vaccines and critical pandemic response capabilities.
The MoU follows recent regulatory and commercial milestones in the country. Mexico’s health regulator, COFEPRIS, has approved Moderna’s 2025–2026 COVID-19 vaccine for individuals aged six months and older. In parallel, the Government of Mexico has awarded a procurement contract for up to 10 million doses of the 2025–2026 vaccine to Logística y Transporte para la Industria de la Salud (Medistik).
Together, these steps position Moderna as a long-term partner in Mexico’s vaccine strategy, combining supply security, local manufacturing, and research collaboration to support public health resilience.
Reference
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico, 10 February 2026, News Release